134 related articles for article (PubMed ID: 2846575)
21. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
[TBL] [Abstract][Full Text] [Related]
22. HT 29, a model cell line: stimulation by the vasoactive intestinal peptide (VIP); VIP receptor structure and metabolism.
Marchis-Mouren G; Martin JM; Luis J; el Battari A; Muller JM; Marvaldi J; Pichon J
Biochimie; 1988 May; 70(5):663-71. PubMed ID: 2844304
[TBL] [Abstract][Full Text] [Related]
23. Characterization of vasoactive intestinal peptide (VIP) receptors in mammalian lung.
Dickinson KE; Schachter M; Miles CM; Coy DH; Sever PS
Peptides; 1986; 7(5):791-800. PubMed ID: 3025822
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a common VIP-PACAP receptor in human small intestinal epithelium.
Salomon R; Couvineau A; Rouyer-Fessard C; Voisin T; Lavallée D; Blais A; Darmoul D; Laburthe M
Am J Physiol; 1993 Feb; 264(2 Pt 1):E294-300. PubMed ID: 8383439
[TBL] [Abstract][Full Text] [Related]
25. Functional and immunological evidence for stable association of solubilized vasoactive-intestinal-peptide receptor and stimulatory guanine-nucleotide-binding protein from rat liver.
Couvineau A; Rouyer-Fessard C; Voisin T; Laburthe M
Eur J Biochem; 1990 Feb; 187(3):605-9. PubMed ID: 2154377
[TBL] [Abstract][Full Text] [Related]
26. Restricted localization of functional vasoactive intestinal peptide (VIP) receptors in in vitro differentiated human colonic adenocarcinoma cells (HT29-D4).
Fantini J; Martin JM; Luis J; Rémy L; Tirard A; Marvaldi J; Pichon J
Eur J Cell Biol; 1988 Aug; 46(3):458-65. PubMed ID: 2846304
[TBL] [Abstract][Full Text] [Related]
27. Identification of nuclear receptors for VIP on a human colonic adenocarcinoma cell line.
Omary MB; Kagnoff MF
Science; 1987 Dec; 238(4833):1578-81. PubMed ID: 2825352
[TBL] [Abstract][Full Text] [Related]
28. Covalent cross-linking of vasoactive intestinal polypeptide to its receptors on intact human lymphoblasts.
Wood CL; O'Dorisio MS
J Biol Chem; 1985 Jan; 260(2):1243-7. PubMed ID: 2981838
[TBL] [Abstract][Full Text] [Related]
29. Isolation of a low molecular mass vasoactive intestinal peptide binding protein.
Brugger CH; Stallwood D; Paul S
J Biol Chem; 1991 Sep; 266(27):18358-62. PubMed ID: 1655745
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of receptors for VIP in rat peritoneal macrophage membranes.
Calvo JR; Guerrero JM; López-Gonzalez MA; Osuna C; Segura JJ
Peptides; 1994; 15(2):309-15. PubMed ID: 8008637
[TBL] [Abstract][Full Text] [Related]
31. Purification of vasoactive intestinal peptide receptor from porcine liver by a newly designed one-step affinity chromatography.
Couvineau A; Voisin T; Guijarro L; Laburthe M
J Biol Chem; 1990 Aug; 265(22):13386-90. PubMed ID: 2165502
[TBL] [Abstract][Full Text] [Related]
32. VIP receptors from porcine liver: high yield solubilization in a GTP-insensitive form.
Voisin T; Couvineau A; Guijarro L; Laburthe M
Life Sci; 1991; 48(2):135-41. PubMed ID: 1847224
[TBL] [Abstract][Full Text] [Related]
33. Pharmacology and molecular identification of vasoactive intestinal peptide (VIP) receptors in normal and cancerous gastric mucosa in man.
Gespach C; Bawab W; Chastre E; Emami S; Yanaihara N; Rosselin G
Biochem Biophys Res Commun; 1988 Mar; 151(2):939-47. PubMed ID: 2831906
[TBL] [Abstract][Full Text] [Related]
34. Solubilization and hydrodynamic characterization of guanine nucleotide sensitive vasoactive intestinal peptide-receptor complexes from rat intestine.
Calvo JR; Couvineau A; Guijarro L; Laburthe M
Biochemistry; 1989 Feb; 28(4):1667-72. PubMed ID: 2541761
[TBL] [Abstract][Full Text] [Related]
35. A fragment of vasoactive intestinal peptide, VIP(10-28), is an antagonist of VIP in the colon carcinoma cell line, HT29.
Turner JT; Jones SB; Bylund DB
Peptides; 1986; 7(5):849-54. PubMed ID: 3025826
[TBL] [Abstract][Full Text] [Related]
36. Cloning and expression of the human vasoactive intestinal peptide receptor.
Sreedharan SP; Robichon A; Peterson KE; Goetzl EJ
Proc Natl Acad Sci U S A; 1991 Jun; 88(11):4986-90. PubMed ID: 1675791
[TBL] [Abstract][Full Text] [Related]
37. Evidence for the formation of a functional complex between vasoactive intestinal peptide, its receptor, and Gs in lung membranes.
Kermode JC; DeLuca AW; Zilberman A; Valliere J; Shreeve SM
J Biol Chem; 1992 Feb; 267(5):3382-8. PubMed ID: 1310685
[TBL] [Abstract][Full Text] [Related]
38. Vasoactive intestinal peptide receptor regulation of cAMP accumulation and glycogen hydrolysis in the human Ewing's sarcoma cell line WE-68.
Van Valen F; Jürgens H; Winkelmann W; Keck E
Cell Signal; 1989; 1(5):435-46. PubMed ID: 2561912
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the immunomodulatory properties of the secretin-glucagon family of peptides on mouse lymphoid cell functions and the demonstration of specific receptors on T cells.
Nguyen TT; Krco CJ; Gores A; Go VL
Immunol Invest; 1987 Nov; 16(7):555-77. PubMed ID: 2832322
[TBL] [Abstract][Full Text] [Related]
40. Characterization of vasoactive intestinal peptide receptors in human colonic epithelial cells.
Broyart JP; Dupont C; Laburthe M; Rosselin G
J Clin Endocrinol Metab; 1981 Apr; 52(4):715-21. PubMed ID: 6259191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
